Home » Stocks » SYN

Synthetic Biologics, Inc. (SYN)

Stock Price: $0.370 USD -0.007 (-1.73%)
Updated December 4, 4:00 PM EST - Market closed

SYN Stock Price Chart

Key Info

Market Cap 7.40M
Revenue (ttm) n/a
Net Income (ttm) -12.58M
Shares Out 19.40M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $0.370
Previous Close $0.377
Change ($) -0.007
Change (%) -1.73%
Day's Open 0.360
Day's Range 0.360 - 0.379
Day's Volume 248,244
52-Week Range 0.270 - 0.710

SYN Stock News

Seeking Alpha - 3 weeks ago

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 6 months ago

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript

About SYN

Synthetic Biologics, a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transpla... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2006
CEO
Steven Shallcross
Employees
11
Stock Exchange
NYSE American
Ticker Symbol
SYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 1.25, which is an increase of 237.84% from the latest price.

Price Target
$1.25
(237.84% upside)
Analyst Consensus: Buy